Soleus Capital Management’s Mereo BioPharma MREO Stock Holding History

Soleus Capital Management’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-299,711	Closed	-$617K	–	112
2025 Q3	$617K	Sell	299,711 -300,000	-50%	-$553K	0.03%	82
2025 Q2	$1.63M	Sell	599,711 -87,242	-13%	-$211K	0.11%	78
2025 Q1	$1.55M	Sell	686,953 -100,000	-13%	-$283K	0.11%	67
2024 Q4	$2.75M	Sell	786,953 -60,000	-7%	-$236K	0.17%	64
2024 Q3	$3.48M	Sell	846,953 -400,000	-32%	-$1.65M	0.27%	69
2024 Q2	$4.49M	Sell	1,246,953 -1,370,000	-52%	-$4.44M	0.4%	63
2024 Q1	$8.64M	Sell	2,616,953 -7,160,466	-73%	-$24.2M	0.64%	48
2023 Q4	$22.6M	Buy	9,777,419 +100,000	+1%	+$191K	2.51%	16
2023 Q3	$12.5M	Buy	+9,677,419	New	+$12.8M	1.15%	31

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Soleus Capital Management's MREO Position: Q4 2025 in Review

Soleus Capital Management sold out of Mereo BioPharma (MREO) in Q4 2025, closing a stake of 299,711 shares — an estimated $617K sold.

Soleus Capital Management first reported a position in MREO in Q3 2023 and held it in 9 quarters. The position peaked at $22.6M in Q4 2023. 70 funds tracked by Wall St. Rank hold MREO as of Q4 2025.

Soleus Capital Management reported no remaining Mereo BioPharma position as of Q4 2025 after selling out during the quarter.
Soleus Capital Management sold 299,711 Mereo BioPharma shares in Q4 2025, an estimated $617K.
Soleus Capital Management first reported a position in Mereo BioPharma in Q3 2023 and held it in 9 quarters.
Soleus Capital Management's Mereo BioPharma position peaked at $22.6M in Q4 2023.
70 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2025.

Based on Soleus Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.